| Literature DB >> 34467580 |
Samira Ansari1, Homa Azizian2, Keyvan Pedrood3, Ali Yavari3, Somayeh Mojtabavi4, Mohammad A Faramarzi4, Shiva Golshani4, Samanesadat Hosseini5, Mahmood Biglar3, Bagher Larijani3, Hossein Rastegar6, Haleh Hamedifar1, Maryam Mohammadi-Khanaposhtani7, Mohammad Mahdavi3.
Abstract
Thirteen new phenoxy-biscoumarin-N-phenylacetamide derivatives (7a-m) were designed based on a molecular hybridization approach as new α-glucosidase inhibitors. These compounds were synthesized with high yields and evaluated in vitro for their inhibitory activity against yeast α-glucosidase. The obtained results revealed that a significant proportion of the synthesized compounds showed considerable α-glucosidase-inhibitory activity in comparison to acarbose as a positive control. Representatively, 2-(4-(bis(4-hydroxy-2-oxo-2H-chromen-3-yl)methyl)phenoxy)-N-(4-bromophenyl)acetamide (7f), with IC50 = 41.73 ± 0.38 µM against α-glucosidase, was around 18 times more potent than acarbose (IC50 = 750.0 ± 10.0 µM). This compound was a competitive α-glucosidase inhibitor. Molecular modeling and dynamic simulation of these compounds confirmed the obtained results through in vitro experiments. Prediction of the druglikeness/ADME/toxicity of the compound 7f and comparison with the standard drug acarbose showed that the new compound 7f was probably better than the standard drug in terms of toxicity.Entities:
Keywords: inhibitors; phenoxy-biscoumarin-N-phenylacetamide; rational drug design; synthesis
Mesh:
Substances:
Year: 2021 PMID: 34467580 DOI: 10.1002/ardp.202100179
Source DB: PubMed Journal: Arch Pharm (Weinheim) ISSN: 0365-6233 Impact factor: 3.751